secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001493152-24-043322
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro sub of BriaCell reports $420K net loss, going concern uncertainty
-------------------------------------------------------------------------

- BriaPro incurred net loss of $420,287 for year ended July 31, 2024; accumulated deficit $440,209 since incorporation in May 2023.
- Total assets $199,797; current liabilities $455,650; shareholders' deficit $405,694; cash balance $1.
- Auditor's report includes material uncertainty paragraph about going concern; company is pre-clinical with no commercial operations.
- Intangible assets (patents) of $199,796 acquired from BriaCell via spinout arrangement on August 31, 2023.
- BriaCell beneficially owns 2/3 of BriaPro's outstanding common shares (31,963,452 of 47,945,178 shares).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224043322/0001493152-24-043322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224043322/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer